FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 692 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Peer-to-peer match-funding initiative raises over £4 million for cancer research May 18, 2021 Doctor Said Her Mammogram Results Were Normal, But Now She’s Fighting... August 25, 2020 NHS ‘understaffed and underequipped’ to tackle cancer, say 3 in 4... May 25, 2022 Ground-breaking trial pilots new tests to detect lung cancer earlier June 16, 2021 Load more HOT NEWS An Important Part of Cancer Caregiving That’s Often Overlooked and How... The RAD51-IF Test Is Feasible for Assessment of the Functional Status... Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical... FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
